UK industry self-regulation for medicine promotion, HCP interactions/hospitality, and transfer-of-value disclosure — checks promotional material and interaction records, not manufacturing/quality documents.
PMCPA / ABPI Code of Practice for the Pharmaceutical Industry (2024) — Regscribe Audit-Readiness Rubric v0
What this is: The ABPI Code of Practice for the Pharmaceutical Industry is the UK pharmaceutical industry's self-regulatory code governing promotion of medicines to UK health professionals, industry interactions with health professionals and healthcare organisations (meetings, hospitality, sponsorship, transfers of value), and provision of information about prescription-only medicines to the public, patients, and journalists. It is administered by the Prescription Medicines Code of Practice Authority (PMCPA) — organisationally part of the ABPI but operating under a separate protocol/constitution — not by a UK statutory regulator (the MHRA enforces the related but separate statutory advertising regulations; PMCPA is the industry's own code-compliance body, with MHRA notified of the outcome of certain cases). This is a genuinely different domain from Regscribe's existing GxP rubrics (GMP, GCP, quality-system, data-integrity): it does not check manufacturing, clinical-trial conduct, or computerised-systems control — it checks promotional and interaction-facing material (advertisements, leaflets, websites, meeting/hospitality records, sponsorship agreements, press releases, patient-facing information) for accuracy, balance, substantiation, and proper sign-off before use.
Sourcing note — read before using this in production scoring: the current version is the "2024 ABPI Code of Practice", which came into operation 1 October 2024 with a short implementation period, becoming fully mandatory 1 January 2025. The clause-by-clause structure and the verbatim/near-verbatim text below were fetched directly from PMCPA's own site, pmcpa.org.uk, specifically the 2024 Interactive ABPI Code of Practice section (https://www.pmcpa.org.uk/the-code/2024-interactive-abpi-code-of-practice/) and its individual clause pages (e.g. .../clause-8-certification-and-examination/, .../clause-12-prescribing-information-and-other-obligatory-information/). A downloadable consolidated PDF of the full Code was also located (https://www.pmcpa.org.uk/media/r0anf5ya/2024-abpi-code.pdf) but was not the source used for clause text below — the interactive per-clause pages were fetched directly and are cited clause-by-clause. Enforcement/failure-pattern statistics below come from PMCPA's own Annual Report 2024 (https://www.pmcpa.org.uk/media/g1lovum4/pmcpa-annual-report-2024-final.pdf), fetched and converted to text with pdftotext -layout — every number quoted below in the "Common failure patterns" section is taken directly from that extracted text, not estimated or paraphrased from a secondary summary.
What was and wasn't independently verified: All 31 clauses (plus Clause 1's definitions) have now been fetched and scored, in two passes. First pass — fetched directly from PMCPA's own interactive-code pages: 1 (definitions), 2 (Upholding Confidence), 5 (High Standards and Suitability), 6 (Information, Claims, Comparisons and Disparagement), 8 (Certification and Examination), 10 (Events/Meetings and Hospitality), 12 (Prescribing Information and Other Obligatory Information), 14 (Information, Claims and Comparisons — promotion to HPs), 19 (Prohibition on Inducements and Inappropriate Payments), 26 (Relations with the Public, Including Patients and Journalists), 28 (Annual Disclosure of Transfers of Value). Second pass (follow-up, same day) — Clauses 3, 4, 7, 9, 11, 13, 15–18, 20–25, 27, 29–31, fetched directly from the consolidated Code PDF (pmcpa.org.uk/media/r0anf5ya/2024-abpi-code.pdf) via pdftotext -layout. One caveat carried from the second pass: its "Common failure pattern" rows are inferred from each clause's own structure, not cross-checked against PMCPA's 2024 Annual Report's named-breach data the way the first pass's failure-pattern rows were — a lighter-weight signal, flagged in Gaps below. Nothing in this document is fabricated: where a clause number, quote, or statistic could not be independently verified against a primary PMCPA source, it is either omitted, or explicitly marked below as unconfirmed.
0. READ THIS FIRST — jurisdiction, enforcement mechanism, and how this differs from Regscribe's other rubrics
This is not a legally-binding statute — it is industry self-regulation with real teeth. The ABPI Code is enforced by the PMCPA's own complaints procedure: a Code Panel investigates and rules on complaints (from health professionals, the public, competitor companies, or PMCPA's own Chief Executive), companies found in breach of certain clauses (notably Clause 2) are publicly named and the ruling advertised at the company's expense, and there is an appeal mechanism to an independent Code of Practice Appeal Board. There is no direct financial penalty scheme comparable to FDA Warning Letters or MHRA inspection findings — the sanction is reputational (public ruling, required corrective statements, potential ABPI membership consequences) plus, in serious cases, referral to the MHRA for the separate statutory advertising regime.
Scope: the Code applies to ABPI member companies, plus (per PMCPA's own site) "over 60 non-member companies that formally accepted Code jurisdiction." A company operating in the UK pharmaceutical space that is neither an ABPI member nor a jurisdiction-accepting non-member is not directly bound by the Code (though MHRA's statutory advertising regulations still apply). This scope question should be checked per-company before treating a Regscribe finding against this rubric as authoritative for that specific company.
How this differs from Regscribe's existing rubrics: every other Regscribe rubric to date (GMP, GCP, Part 11, Annex 11, ISO standards, etc.) checks how a product is made, tested, or its records controlled. This rubric checks what a company says about a medicine, to whom, and what it gives people in the process — promotional copy, meeting sponsorship records, and disclosure filings, not batch records or validation packages. The closest structural analogue elsewhere in Regscribe is Part 11/Annex 11's signature and record-integrity requirements — the Code's Clause 8 (Certification) plays a comparable "nothing goes out the door without a named, accountable sign-off" role for promotional material that electronic-signature clauses play for GxP records.
Rubric legend
Each row: Requirement (plain language / near-verbatim) → Citation → Evidence that demonstrates compliance → Common failure pattern
Full Code structure (confirmed via PMCPA's own site navigation)
ABPI Principles
Section 1 — Overarching Requirements: Clause 1 (Scope and Definitions) · Clause 2 (Upholding Confidence in the Industry) · Clause 3 (Obligations) · Clause 4 (Responsibilities) · Clause 5 (High Standards and Suitability) · Clause 6 (Information, Claims, Comparisons and Disparagement) · Clause 7 (Use of Quotations) · Clause 8 (Certification and Examination) · Clause 9 (Training) · Clause 10 (Events/Meetings and Hospitality)
Section 2 — Promotion to Health Professionals: Clause 11 (Marketing Authorisation and Temporary Supply Authorisation) · Clause 12 (Prescribing Information and Other Obligatory Information) · Clause 13 (Abbreviated Advertisements) · Clause 14 (Information, Claims and Comparisons) · Clause 15 (High Standards, Format and Suitability) · Clause 16 (Material and Distribution) · Clause 17 (Representatives)
Section 3 — Interactions with Health Professionals: Clause 18 (Information, Claims and Comparisons) · Clause 19 (Prohibition on Inducements and Inappropriate Payments and the Provision of Items to Health Professionals and Other Relevant Decision Makers) · Clause 20 (Collaborative Working with Organisations) · Clause 21 (Provision of Medicines and Samples) · Clause 22 (Non-Interventional Studies of Marketed Medicines)
Section 4 — Broad Stakeholder Interactions: Clause 23 (Donations and Grants) · Clause 24 (Contracted Services) · Clause 25 (Relationships with Health Professionals and Organisations)
Section 5 — Public and Patient Organisation Interactions: Clause 26 (Relations with the Public, Including Patients and Journalists) · Clause 27 (Relationships with Patient Organisations)
Section 6 — Annual Disclosure Requirements: Clause 28 (Annual Disclosure of Transfers of Value to Health Professionals, Other Relevant Decision Makers and Healthcare Organisations) · Clause 29 (Annual Disclosure of Contracted Services, Donations, Grants and Sponsorship Provided to Patient Organisations) · Clause 30 (Annual Public Disclosure of Contracted Services Provided by the Public, Including Patients and Journalists) · Clause 31 (Timings, Duration and Retention of Disclosure Information)
Only the clauses independently fetched and read are scored in detail below. This deliberately prioritises the clauses most directly checkable against an uploaded document — promotional-material content requirements, claims substantiation, certification sign-off, hospitality/meeting documentation, and transfer-of-value disclosure.
Section 1 — Overarching Requirements
Clause 2 — Upholding Confidence in the Industry
| |
|---|
| Requirement | "Activities or materials must never be such as to bring discredit upon, or reduce confidence in, the pharmaceutical industry." A breach finding under this clause represents "particular censure" and is reserved for serious circumstances — PMCPA's own guidance gives examples: endangering patient safety or public health, excessive hospitality, inducements to prescribe, unacceptable payments, failure to adequately address a prior undertaking to stop a breach, promoting a medicine before it has a marketing authorisation, incompetent employee/agent conduct, or multiple serious similar breaches in the same therapeutic area in a short time. |
| Citation | ABPI Code 2024, Clause 2 |
| Evidence of compliance | No document-level "evidence" satisfies Clause 2 directly — it is a backstop, catch-all clause the Panel applies when the severity or pattern of an underlying breach (of Clause 5, 6, 9, 12, etc.) is judged serious enough to also discredit the industry. Flag any finding against another clause below as a potential Clause 2 escalation risk when it involves patient-safety-relevant misinformation, repeat/systemic failure across multiple pieces of material, or promotion of an unlicensed medicine/indication — do not score Clause 2 as a standalone checklist item. |
| Common failure pattern | Per PMCPA's own 2024 Annual Report, of companies ruled in breach of the Code for complaints received in 2023, a marked subset were specifically flagged as "in breach of Clause 2" (11 cases / 11 rulings for that cohort per the report's breach table) — Clause 2 breaches trigger PMCPA's most visible sanction: the company is publicly named, the ruling advertised at the company's own cost, and this can extend to a requirement to circulate the ruling to relevant staff/customers. |
Clause 3 — Obligations
| Clause | Requirement (near-verbatim) | Evidence |
|---|
| 3.1 | "A medicine must not be promoted prior to the grant of the marketing authorisation which permits its sale or supply." | Confirmation of current marketing-authorisation status before any promotional claim about the medicine is made — a boundary check on timing, not just content. |
| 3.2 | "Prescription only medicines must not be advertised to the public," except for health-minister-approved vaccination/other campaigns. | Same POM-to-public boundary check as Clause 26.1 (the patient-facing analogue) — flag any public-facing document naming a POM outside the narrow campaign exception. |
| 3.3 | Where a company has given an undertaking following a Code ruling, it "must ensure that it complies with that undertaking." | A tracked register of prior undertakings, checked against current material to confirm the specific defect previously ruled upon has not recurred. |
| 3.4 | Companies must comply with all applicable codes, laws and regulations — including, where cross-border, both the home-country code and the destination-country code (more restrictive requirement applies in case of conflict). | For any cross-border material/event, confirmation of which national code(s) apply and that the more restrictive standard was used. |
| 3.5 | "Gifts for personal benefit (such as sporting or entertainment tickets, social courtesy gifts) are prohibited" to health professionals, ORDMs, or individuals associated with a healthcare/patient organisation — directly or indirectly. Cash, cash equivalents, or services conferring personal benefit are also prohibited. | Gift/benefit register checked specifically for personal-benefit items (as distinct from the patient-benefit/professional-purpose items permitted under Clause 10.5/19.2/23) — cash-equivalent instruments (vouchers etc.) are a specific red flag. |
| 3.6 | "Materials and activities must not be disguised promotion." | Cross-reference to the more detailed disguised-promotion rule at Clause 15.6 — any material presenting itself as non-promotional (safety information, independent editorial) while functioning as promotion. |
| 3.7 | "Each company must appoint a senior employee to be responsible for ensuring that the company meets the requirements of the Code" — presumed to be the managing director/chief executive or equivalent absent other formal arrangement. | Confirmation a named senior individual is documented as Code-responsible, distinct from the Clause 8 certification signatories. |
| Common failure pattern (whole section) | Structurally, 3.1/3.2 (pre-authorisation and public-advertising prohibitions) and 3.5 (personal-benefit gifts) are the most objectively checkable — a clear yes/no against marketing-authorisation status or gift type — versus 3.6's disguised-promotion test, which (like Clause 26.1) is fact-sensitive and tone-dependent rather than a keyword check. | |
Clause 4 — Responsibilities
| Clause | Requirement (near-verbatim) | Evidence |
|---|
| 4.1 | Companies must have a scientific service to "compile and collate all information received from any source about the medicines which they market." | Confirmation a named scientific service function exists and receives/processes safety and medical information — distinct from the promotional-approval function. |
| 4.2 | A scientific service — including a UK-registered medical practitioner or pharmacist — must approve and supervise non-interventional studies, including certifying the protocol. | The Clause 4.2-qualified individual's certification of the specific study protocol on file (this is the same protocol-certification referenced under Clause 22.1). |
| 4.3 | Companies must document and publicly disclose transfers of value to European health professionals/ORDMs/healthcare organisations under Clause 28 (including company employees who are practising HPs). | This is the parent obligation for Clause 28's disclosure mechanism — cross-reference to the Clause 28 filing. |
| 4.4 | Companies must document and disclose annually donations/grants/sponsorship (financial, non-financial, benefit-in-kind) to patient organisations, and contracted-service fees paid to patient organisations (including via individuals representing them), per Clause 29. | Cross-reference to Clause 29 disclosure filing for the patient-organisation-facing analogue of Clause 28. |
| 4.5 | Companies must document and disclose annually fees/expenses to individual members of the public (including patients/journalists) for contracted services, per Clause 30. | Cross-reference to Clause 30 disclosure filing. |
| 4.6 | Clinical trial details must be disclosed per the Joint Position on Disclosure of Clinical Trial Information (registries/databases) and the Joint Position on Publication of Clinical Trial Results; the company website's home page must state where clinical-trial details can be found; trials must be registered within 21 days of patient-enrolment initiation. | A working, current link/statement on the company homepage directing to clinical-trial disclosure; registration-timing record for any trial referenced showing the 21-day window was met. |
| 4.7 | Non-interventional-study summary details/results must be published "in a manner consistent with" the Clause 4.6 clinical-trial obligations. | Confirmation non-interventional study publication follows the same disclosure discipline as clinical trials, not a lower bar. |
| 4.8 | "Companies are responsible for information about their products which is issued by their agencies, e.g. communications, advertising, etc." | Contractual Code-compliance flow-down to agencies (this is the general form of the same principle Clause 5.2 states for personnel generally). |
| Common failure pattern (whole section) | Clause 4.6's "details of clinical trials must be limited to factual and non-promotional information... must not constitute promotion" is a common failure vector — advance/horizon-scanning-style disclosure (also relevant to Clause 3.1's supplementary information) drifting into promotional framing before a marketing authorisation exists. | |
Clause 7 — Use of Quotations
| Clause | Requirement (near-verbatim) | Evidence |
|---|
| 7.1 | "Quotations from medical and scientific literature or from personal communications must be faithfully reproduced, accurately reflect the meaning and current views of the author and otherwise comply with the Code. The precise source of the quotation must be identified." Quotations may only be adapted to comply with the Code, and any such amendment must be clearly stated. | Each quotation checked against its original source for faithful reproduction and current authorial intent (not just accuracy at time of original publication); any edited quotation flagged as amended on its face. |
| 7.2 | Quotations from public broadcasts (radio/TV) or private occasions (conferences, symposia) "must not be used without the formal permission of the speaker." | A permission record for any quotation sourced from a broadcast or private/conference occasion, distinct from published-literature quotations. |
| Common failure pattern | Per the clause's own supplementary information, a quotation can be individually accurate yet still breach the Code if it triggers another clause's prohibition (the worked example given is quoting a paper that called a medicine "safe and effective," which would breach Clause 6.4's unqualified-"safe" rule even though it's a faithful quotation) — i.e., quotation fidelity does not override other substantive clauses. | |
Clause 5 — High Standards and Suitability
| Clause | Requirement (verbatim/near-verbatim) | Evidence |
|---|
| 5 (chapeau) | "The special nature of medicines and the audience to which the information is directed require that the standards set for information about medicines are higher than those which might be acceptable for general commodity communications and advertising." | Frame every other content check below against this elevated-standard principle — generic advertising-industry norms are not the bar. |
| 5.1 | "Companies must maintain high standards at all times." | A documented internal policy setting Code-compliance expectations for all promotional/interaction activity, plus training records (see Clause 9, not independently verified) evidencing the policy is actually operationalised, not just written. |
| 5.2 | "All company personnel must maintain a high standard of ethical conduct in the discharge of their duties and comply with all relevant requirements of the Code." Companies remain responsible for the actions of personnel, including contractors and third parties acting on their behalf. | Evidence that third-party/agency-produced material and conduct is held to the same standard as in-house material — e.g. contractual Code-compliance obligations flowed down to agencies, congress organisers, and contracted sales/medical-science-liaison staff. |
| 5.3 | "All material and activities must recognise the special nature of medicines and respect the professional standing or otherwise of the audience to which they are directed and must not be likely to cause offence." Naked imagery used merely to attract attention, and "teaser" campaigns lacking substantive information, are specifically prohibited. | Material reviewed for tone/imagery appropriateness to the named audience (health professional vs. patient vs. general public) as a distinct check from factual accuracy. |
| 5.6 | "Material relating to medicines ... must clearly indicate the role of that pharmaceutical company" (i.e., sponsorship/origin must be declared). | A visible, unambiguous sponsorship/company-identification statement on the face of the material — this is the general form of the same disclosure requirement Clause 10.10 applies specifically to sponsored events. |
| Common failure pattern (whole section) | Per PMCPA's 2024 Annual Report breach-company listing, Clause 5.1 ("high standards") is cited alongside Clause 6.1 and Clause 2 in multiple named 2023-cohort rulings as a companion finding — in practice, Clause 5.1 rarely stands alone; it is typically ruled breached together with a specific factual clause (misleading claim, missing prescribing information, uncertified material), functioning as a general "this fell short of the standard expected" finding layered on top of the specific defect. Regscribe should treat a Clause 5.1/6.1/2 co-occurrence pattern as expected, not anomalous. | |
Clause 6 — Information, Claims, Comparisons and Disparagement
| Clause | Requirement (verbatim/near-verbatim) | Evidence |
|---|
| 6.1 | "Information, claims and comparisons must be accurate, balanced, fair, objective and unambiguous" and based on an up-to-date evaluation of the evidence; material must be sufficiently complete to let the recipient form their own opinion of the therapeutic value of the medicine. | Claims cross-checked against current SPC/marketing authorisation and current clinical evidence; no cherry-picked positive data without the balancing risk/limitation information needed for an independent professional judgment. |
| 6.2 | "Any information, claim or comparison must be capable of substantiation." Substantiation must be provided to health professionals/decision-makers on request, and clinical trial data underlying claims must be properly registered/disclosed per Clause 4.6 (Clause 4 not independently verified). | A retrievable substantiation file/reference list mapped to each specific claim in the material — not a general bibliography — such that any individual claim in the document can be traced to its supporting source on demand. |
| 6.3 | Artwork, illustrations, graphs and tables must comply with the Code; when sourced from published studies, references are required; visual presentations must give "a clear, fair, balanced view" and not mislead through selective/distorted presentation. | Every graph/chart/table in the material sourced with a full reference; visual scaling and axis choices checked for distortion (e.g. truncated y-axis exaggerating an effect size). |
| 6.4 | Adverse-reaction information must "reflect available evidence or be capable of substantiation"; the term "safe" must not be used without qualification. | No unqualified "safe" claims anywhere in the material; adverse-event framing checked against the current SPC safety section. |
| 6.5 | The term "new" must not be used for a product or indication that has been available in the UK for more than twelve months. | Product/indication launch-date tracking cross-checked against any "new" claim in the material being reviewed. |
| 6.6 / 6.7 | Prohibits disparaging "medicines, products and activities of other pharmaceutical companies" (6.6), and disparaging "health professions and the clinical and scientific opinions of health professionals" (6.7). | Competitor-comparison language checked for disparagement, not just factual accuracy — a comparison can be accurate and still breach 6.6 if presented in a disparaging manner. |
| Common failure pattern (whole section) | Clause 6.1 (misleading claim) and Clause 6.2 (unsubstantiated claim) are, per the clause pages and PMCPA's own named-breach examples, among the most frequently co-cited factual clauses in rulings — a claim that is technically traceable to a source but presented in a way that overstates what that source actually shows is a recurring pattern (accurate underlying data, misleading presentation of it), distinct from a claim with no source at all. | |
Clause 8 — Certification and Examination
This is the closest analogue in this Code to Regscribe's existing electronic-signature/approval checks (Part 11 §11.70, Annex 11 §14) — nothing may be used until a named, accountable individual has certified it.
| Clause | Requirement (verbatim/near-verbatim) | Evidence |
|---|
| 8.1 | "Promotional material must not be issued unless its final form ... has been certified by one person on behalf of the company." The certifier must be a registered medical practitioner, UK pharmacist, or (for dental-only products) a UK-registered dentist, and cannot be the person who developed the material — a mandatory segregation-of-duties requirement. Certification may use a validated electronic signature; if the final proof is certified electronically but then printed, the printed version must be separately examined and signed before use. All promotional content requires certification — including audio/audiovisual material (with a written transcript available), material on databases/interactive systems/the internet, and representatives' briefing materials. | A signed/electronically-signed certificate on file, naming a qualified certifier who is demonstrably not the material's author, dated before the material's first use/issue, covering the exact final form of the material (no post-certification amendments without re-certification). |
| 8.2 | Events/meetings involving travel outside the UK must be certified in advance by a signatory or an "appropriately qualified person" (AQP) signatory, who need not be a medical practitioner or pharmacist. Certification requires review of "the programme, the venue, the reasons for using that venue, the intended audience." | A dated pre-event certification record addressing programme content, venue choice and rationale, and intended audience — distinct from, and in addition to, Clause 8.1 material certification. |
| 8.3 | Additional material requiring advance certification includes: educational material for the public/patients relating to diseases or medicines but not intended as promotion; patient-organisation working materials; collaborative-working documentation; patient support materials; donation/grant agreements; non-interventional study protocols. Other company-issued material not requiring full certification (corporate advertising, press releases, market research) should still be "examined by a signatory or an AQP" to check it doesn't contravene the Code. | A certification or examination record for each item in this broader category, distinct from standard promotional-material certification but still evidencing named-individual sign-off. |
| 8.4 | The names of nominated signatories, with qualifications, must be notified in advance to the MHRA and to the PMCPA; changes must be promptly notified. | A current, MHRA/PMCPA-notified signatory list, checked against who actually signed the certificate on file — a certificate signed by someone not on the notified list is a documentary red flag independent of the certifier's actual qualifications. |
| 8.5 | The certificate must confirm the signatory examined the material to ensure it is: "in accordance with the requirements of the relevant regulations relating to advertising and this Code"; "not inconsistent with the marketing authorisation and the summary of product characteristics"; and "a fair and truthful presentation of the facts about the medicine." Material still in use must be recertified at intervals of no more than two years. | A certificate reciting (or demonstrably covering) all three of these specific attestations — a certificate that only confirms "legally reviewed" without the SPC-consistency and fair-presentation attestations is incomplete; and a recertification date tracker showing no certified item has exceeded a two-year in-use window without recertification. |
| 8.6 | Companies must preserve certificates, the material in its certified final form, and details of dissemination (recipients, method, date) — for international events, also the programme, venue and rationale, audience, anticipated/actual costs, and nature of hospitality. Retention: not less than three years after the final use of the material or the date of the event/meeting. | A retrievable archive tying each certificate to its exact certified final-form artifact and dissemination log, retained for the full three-year post-use window — a certificate that can't be matched to the specific version of material actually distributed is not compliant evidence. |
| Common failure pattern (whole section) | Named 2023-cohort breach examples referencing Clause 8.1 co-occur with Clause 12 (prescribing information) and Clause 5.1/2 findings — in practice, uncertified or improperly-certified material and missing/defective obligatory information (Clause 12) tend to be found together, consistent with certification (Clause 8.5's own attestation) being the control that should have caught a Clause 12 defect before issue. A missing or stale (>2-year) certificate is therefore a leading indicator worth flagging even before checking the material's substantive content. | |
Clause 9 — Training
| Clause | Requirement (near-verbatim) | Evidence |
|---|
| 9.1 | "All relevant personnel, including representatives, and members of staff, and others retained by way of contract, concerned in any way with the preparation or approval of material or activities covered by the Code must be fully conversant with the Code and the relevant laws and regulations." | Training records covering everyone who touches material preparation/approval — not just representatives — including contracted third parties. This is the evidence Clause 5.1 already points to. |
| 9.2 | All personnel (including contracted) must be "fully conversant with pharmacovigilance requirements relevant to their work, and this must be documented." | Documented pharmacovigilance training records, distinct from general Code training. |
| 9.3 | Representatives must have "adequate training and sufficient scientific knowledge to enable them to provide full and accurate information about the medicines which they promote." | Product-specific scientific training records for representatives, separate from general Code/pharmacovigilance training. |
| 9.4 | Representatives must take an appropriate (Ofqual-accredited, Level 3+/Diploma-equivalent) examination within their first year of employment and pass within two years; a company using a non-ABPI provider must demonstrate equivalence. Extensions require PMCPA Chief Executive approval for extenuating circumstances. | Examination-status tracker per representative, showing exam taken/passed within the mandated windows, or a documented PMCPA-approved extension on file for any exception. |
| 9.5 | "Details of the numbers of representatives who have passed an examination, together with the examination status of others, must be provided to the PMCPA on request." | A retrievable, currently-accurate roster of representative examination status, ready for on-request disclosure. |
| Common failure pattern (whole section) | The two-year hard cap on unexamined representative employment (9.4) combined with the "cannot avoid via job-switching between companies" rule (examination clock is cumulative across employers) is a specific, checkable data point — an employment/examination-date mismatch exceeding two years cumulative, absent a documented PMCPA extension, is a clean failure signal. | |
Section 2 — Promotion to Health Professionals
Clause 11 — Marketing Authorisation and Temporary Supply Authorisation
| Clause | Requirement (near-verbatim) | Evidence |
|---|
| 11.1 | "A medicine must not be promoted prior to the grant of the marketing authorisation which permits its sale or supply," subject to the Clause 11.3 exception. | Marketing-authorisation grant date checked against first-promotion date of the material under review. |
| 11.2 | Promotion "must be in accordance with the terms of its marketing authorisation and must not be inconsistent with the particulars listed in its summary of product characteristics," subject to 11.3. | Every claim/indication in the material cross-checked against the current SPC — this is the clause underlying the SPC-consistency attestation in Clause 8.5's certification requirement. |
| 11.3 | A medicine with only a temporary supply authorisation "must not be promoted unless it is part of a campaign that has been approved by the health ministers." | Health-minister campaign-approval record for any material promoting a temporarily-authorised medicine. |
| Common failure pattern | The clause's own supplementary information flags international-event promotion of medicines not UK-authorised as a specific recurring risk area — material must be clearly/prominently labelled as lacking UK authorisation, name at least one major country where it IS authorised, and be certified to a modified (fair-and-truthful-only) standard under Clause 8 — a multi-part checklist easy to partially miss. | |
Clause 12 — Prescribing Information and Other Obligatory Information
This is the most directly document-checkable clause in the Code — it specifies literal required content on the face of promotional material.
| Clause | Requirement (near-verbatim) | Evidence |
|---|
| 12.1 | Prescribing information must be "provided in a clear and legible manner" on all promotional material except abbreviated advertisements, positioned for easy reference; delivery may be via text, a QR code, or a direct single-click link depending on medium (printed, digital accessed independently, or digital shown to a recipient in person). | Prescribing information present and legible on the material; where a QR code/link is used, confirmation the link target is current and the mechanism is permitted for that specific medium/context. |
| 12.2 | Prescribing information must include: legal classification (e.g. POM status); cost information (limited exceptions for certain journals); and eight further elements — medicine name, active ingredients, authorised indication(s), dosage/administration, adverse reactions, warnings, marketing-authorisation number/holder details, and date of preparation. The SPC may be used in place of the eight elements entirely. | A checklist confirming each of the enumerated elements is present verbatim or via a clearly-referenced current SPC — not a partial subset. |
| 12.3 | Where prescribing information is not immediately apparent, "a clear prominent statement as to where the prescribing information can be found" is required, with specific minimum sizing (lowercase 'x' height ≥2mm) for journal advertisements. | A prominent, correctly-sized signpost statement present wherever prescribing information isn't directly on the same page/screen. |
| 12.4 | The non-proprietary name (or active ingredients) must appear "immediately adjacent to the most prominent display of the brand name," in bold, meeting minimum size/area requirements relative to the brand name. | Visual check of brand-name placement against the non-proprietary-name adjacency and formatting rule — a common, easily-missed layout defect. |
| 12.5 | Promotional material (excluding professional publications) must include "the date on which the promotional material was created or last revised." | A visible creation/revision date on the material — distinct from, but often confused with, the certification date under Clause 8. |
| 12.6 | A prominent adverse-event reporting statement is mandatory: "Adverse events should be reported. Reporting forms and information can be found at [MHRA Yellow Card website]. Adverse events should also be reported to [relevant pharmaceutical company]." | The statement present verbatim (or materially equivalent), naming both the MHRA Yellow Card route and the specific company's own reporting channel — a statement naming only one of the two is incomplete. |
| 12.7 | Where the licensing authority requires additional-monitoring status to be flagged, an inverted black equilateral triangle (minimum 5mm per side, scaled for advertisement size) must appear adjacent to the product name. | Black triangle present, correctly sized, and correctly placed for any medicine actually subject to additional monitoring — confirmed against the medicine's current regulatory status, not assumed from a prior version of the material. |
| Common failure pattern (whole section) | Named 2023-cohort breach rulings referencing multiple Clause 12 sub-clauses together (12.1, 12.3, 12.4, 12.6, alongside Clause 8.1 and 5.1) were found in PMCPA's own source material — the pattern is consistently partial compliance (e.g. prescribing information present but the adverse-event statement or signpost missing/undersized) rather than wholesale omission, which is exactly the kind of granular, checklist-style content gap a document-level tool like Regscribe is well suited to catch. | |
Clause 13 — Abbreviated Advertisements
| Clause | Requirement (near-verbatim) | Evidence |
|---|
| 13.1–13.2 | Abbreviated advertisements are exempt from full prescribing-information requirements only if limited in size/content per this clause, and may only appear in professional publications (not audiovisual, interactive systems, internet, or journals-online, and never as a loose insert). | Confirmation the medium is a genuine professional publication before applying the abbreviated-ad exemption — a digital placement using abbreviated-ad content is a straightforward Clause 13.2 breach. |
| 13.3 | Maximum size 420 square centimetres. | Physical/digital dimension check against the 420cm² ceiling. |
| 13.4 | Permitted content is restricted to: medicine name, non-proprietary name/active ingredients, at least one SPC-consistent indication — and nothing else (no dosage, pack size, or cost, except where that information is itself the substantiated reason the medicine is recommended). | Content-inclusion check confirming no information beyond the enumerated list appears. |
| 13.5 | Non-proprietary name/active-ingredient list must be sized per the Clause 12.4-equivalent adjacency/sizing rule (≥2mm x-height or area no less than the brand name). | Same layout check as Clause 12.4, applied to the abbreviated-ad format specifically. |
| 13.6 | Mandatory Yellow Card adverse-event statement, verbatim-equivalent to Clause 12.6. | Statement present verbatim; if the MHRA website address changes, the new address must be adopted within one year. |
| 13.7 | Black-triangle symbol required where applicable, sized per specified minimums (3mm sides up to A5, 5mm above). | Triangle present, correctly sized for the advertisement's dimension band. |
| 13.8–13.9 | May include a concise SPC-consistent reason-for-recommendation statement; marketing authorisation numbers and references must NOT be included. | Confirmation no MA number appears — an inclusion here (unlike Clause 12.2, where it's required) is itself a defect. |
| Common failure pattern | The clause's restrictive "abbreviated ads cannot appear in audiovisual/interactive/internet media" rule (13.2) combined with the prohibition on MA numbers (13.9, the inverse of Clause 12's requirement) makes Clause 13 a common source of format-confusion errors when material is repurposed from a full advertisement into an abbreviated one without re-checking the content rules from scratch. | |
Clause 14 — Information, Claims and Comparisons (Promotion to Health Professionals)
| Clause | Requirement (near-verbatim) | Evidence |
|---|
| 14.1 | Comparisons are permitted only where "not misleading" and compare medicines for the same needs using "material, relevant, substantiable and representative features," without creating confusion with a competitor's product, discrediting a competitor's trademark, or taking unfair advantage of a competitor's reputation. | Any head-to-head comparison checked against all four named criteria (material, relevant, substantiable, representative), not just factual accuracy of the underlying numbers. |
| 14.2 | "When promotional material refers to published studies, clear references must be given" — extending to quotations, tables, graphs, and artwork. | Every study reference, quotation, and data visualization individually citation-linked. |
| 14.3 | Relevant data must be provided to a requesting health professional "as soon as possible, and certainly within ten working days." | A documented process/SLA for substantiation requests, with evidence of the 10-working-day turnaround being met in practice — process-only documentation without turnaround evidence is a partial gap. |
| 14.4 | Promotion must "encourage the rational use of a medicine by presenting it objectively"; exaggerated claims and superlatives are prohibited except where they represent "a clear fact about a medicine." | Superlative language (e.g. "the best," "unique," "leading") checked for a specific, substantiable factual basis before being allowed to stand. |
| 14.5 | For multi-screen/multi-page advertisements, "none of the individual screens or pages ... must be false or misleading when read in isolation." | Each individual screen/page of a digital or multi-page advertisement independently checked, not just the advertisement as a complete sequence. |
| Common failure pattern (whole section) | Superlative/exaggeration claims (14.4) and unreferenced comparative claims (14.1/14.2) are the two sub-patterns most visible in named breach material — both are checkable at the sentence level in an uploaded document, making Clause 14 one of the higher-value clauses for automated pre-certification screening. | |
Clause 15 — High Standards, Format and Suitability
| Clause | Requirement (near-verbatim) | Evidence |
|---|
| 15.1 | Must not imitate other companies' devices/copy/slogans/layout in a way likely to mislead or confuse. | Comparative layout/branding check against known competitor material. |
| 15.2 | Must not reference the Commission on Human Medicines, MHRA, or the licensing authority unless specifically required by the licensing authority. | Content scan for unauthorised regulatory-body references. |
| 15.3 | Reproductions of official documents require written permission from the appropriate body. | Permission record for any reproduced official document. |
| 15.4 | Postcards/exposed mailings/envelopes/wrappers must not carry public-advertising-style matter (Clause 26.1 cross-reference). | Exterior/visible-surface content check on any mailed material. |
| 15.5 | Telephone, text, email, fax, automated calling, and other digital communications for promotional purposes require prior recipient permission; remote detailing requires upfront disclosure of company, caller role, and call purpose. | Documented opt-in/permission record per channel; remote-detailing call scripts confirmed to include the mandated upfront disclosures. |
| 15.6 | "Promotional material and activities must not be disguised" — the responsible company's identity must be obvious; material must not imply non-promotional content (e.g., that it's safety information). | Same disguised-promotion check as Clause 3.6, applied specifically to format/presentation rather than the underlying content. |
| Common failure pattern (whole section) | 15.5's channel-specific permission requirement is a two-part trap similar to 10.4: permission to use a channel at all (e.g., email) versus the further obligation to include an unsubscribe mechanism on outbound promotional emails specifically — a company with valid initial consent but no unsubscribe path per-email is a partial gap. | |
Clause 16 — Material and Distribution
| Clause | Requirement (near-verbatim) | Evidence |
|---|
| 16.1 | POM promotional material directed at a UK audience and provided on the internet must comply with all relevant Code requirements. | Website/digital promotional-material audit against the full Code, not a reduced digital-specific subset. |
| 16.2 | Such material may be advertised in a relevant, independently-produced electronic journal for HPs/ORDMs even if publicly accessible, provided each page is labelled as HP-intended. | Page-level "intended for health professionals" labelling check on electronic-journal placements. |
| 16.3 | "Restraint must be exercised on the frequency of distribution and on the volume of promotional material distributed." | Distribution-frequency/volume review — informational content sparseness is specifically named as a factor that increases scrutiny of frequency. |
| 16.4 | Mailing lists must be current; removal requests "complied with promptly," and no name restored except at the addressee's request/permission. | Mailing-list removal-request turnaround record. |
| 16.5 | Reprints must not be proactively provided unless peer-reviewed, and must be accompanied by prescribing information and adverse-event reporting information, with particular attention to Clauses 12.1/12.2. | Peer-review status check plus confirmation the reprint packet includes prescribing information and the Yellow Card statement. |
| Common failure pattern | Proactive reprint provision (16.5) "constitutes promotion of that medicine" in full — a reprint distributed without the accompanying Clause 12.1/12.2 prescribing-information package is a common gap, since reprints are sometimes treated internally as "just an article" rather than promotional material subject to the full obligatory-content regime. | |
Clause 17 — Representatives
| Clause | Requirement (near-verbatim) | Evidence |
|---|
| 17.1 | Same adequate-training/scientific-knowledge requirement as Clause 9.3. | Cross-reference to Clause 9 training records. |
| 17.2 | "Representatives must not employ any inducement or subterfuge to gain an interview. No fee should be paid or offered for the grant of an interview." | Interview-solicitation script/process review for inducement language; confirmation no interview-access fee exists. |
| 17.3 | Call frequency/timing/duration/manner "must not cause inconvenience"; calls on a given doctor/prescriber "should not normally exceed three on average" per year, excluding group events, doctor-requested visits, and adverse-reaction follow-ups. | Call-log records checked against the ~3-calls/year guideline, with the named exclusions applied correctly (not miscounted as part of the cap). |
| 17.4 | At the outset of an interview (or when seeking one), representatives "must... take reasonable steps to ensure that they do not mislead as to their identity or that of the company they represent." | Introduction-script review for identity/company disclosure. |
| 17.5 | Representatives must forward information they receive about medicine use — particularly adverse-reaction reports — "without delay" to the Clause 4.1 scientific service. | Adverse-event escalation-time record from representative to scientific service. |
| 17.6 | Representatives must be paid a "fixed, basic salary," with any sales-proportional addition not constituting "an undue proportion of their remuneration." | Remuneration-structure review confirming sales-linked pay is not the dominant component — the representative-level analogue of Clause 23's prohibition on sales-linked bonus schemes for contracted service providers. |
| 17.7 | Representatives must provide, or have available, an SPC copy for each medicine promoted (electronic copy acceptable); not required if the discussion was initiated by the person called upon. | SPC-availability confirmation, with the narrow initiated-by-recipient exception correctly applied. |
| 17.8 | Briefing material — "the training material used to instruct representatives about a medicine and the instructions given to them as to how the product should be promoted" — must comply with the Code and is subject to Clause 8 certification; must not advocate any course of action likely to breach the Code; must be available to MHRA/PMCPA on request. | Certification record for briefing material (the specific evidence Clause 8.1 already anticipates); confirmation the material contains no Code-breaching instructions to representatives. |
| Common failure pattern (whole section) | The 17.3 call-frequency guideline is structurally similar to 10.8's subsistence ceiling — a "should not normally exceed" soft cap rather than a hard rule — meaning the failure pattern is repeated/systematic excess without documented justification, not a single over-limit call. Companies employing contract representatives remain fully responsible for their Clause 17 and Clause 9 compliance. | |
Section 3 — Interactions with Health Professionals
Clause 10 — Events/Meetings and Hospitality
| Clause | Requirement (near-verbatim) | Evidence |
|---|
| 10.1 | Companies may hold, sponsor, or support delegate attendance at events/meetings meeting Code requirements, but hospitality is permitted only in association with scientific meetings, promotional meetings, scientific congresses, and similar training events. The event's educational content — not hospitality or venue — must be what attracts delegates; venues must be appropriate and not lavish/extravagant; subsistence, accommodation, and travel costs "must be strictly limited to the main purpose"; sponsorship of entertainment (sporting/leisure activities) is prohibited; economy air travel is required (premium economy permissible only for flights over six hours). PMCPA's own evaluation heuristic: "Would you and your company be willing to have these arrangements generally known?" | A written internal events/hospitality policy; per-event documentation showing venue rationale, programme content, and cost breakdown consistent with an educational (not lavish) purpose; travel-class records consistent with the six-hour economy/premium-economy rule. |
| 10.2 | "No payment may be offered or paid to individuals to compensate merely for the time spent in attending events/meetings." | Confirmation no attendance-only "time compensation" payment exists separate from any legitimate speaker/consultancy fee for actual work performed. |
| 10.4 | Support to an individual health professional/other relevant decision maker to attend an event requires a written agreement documenting what was agreed, broken down by cost category (registration, accommodation, travel); the rationale for providing the support must be documented prior to the support being provided. | A signed written agreement per supported individual, itemised by cost category, plus a separate pre-provision rationale record — two distinct documentary requirements, not one combined document. |
| 10.5 / 10.6 | Attendees at company-organised events may receive inexpensive pens/pencils/notepads (no medicine names/information; company name permitted) — maximum one item of each type per person, total cost per individual ≤£6 excluding VAT. The same £6 cap and no-medicine-branding rule applies to items placed in conference bags at independently-organised meetings, which additionally must not be distributed from exhibition stands. | Item-cost records evidencing the £6/person cap was not exceeded; content check confirming no medicine name/information appears on any such item. |
| 10.7 | Quizzes are acceptable only if non-promotional, genuine tests of skill/knowledge, respectful of professional standing, offer no prizes, and are part of formal proceedings (not run from exhibition stands). Competitions/quizzes used as promotion techniques are prohibited outright. | Quiz format/prize-structure review against all named conditions simultaneously. |
| 10.8 | Subsistence (food/drink) cost per person "must not exceed £75, excluding VAT and gratuities" — and this ceiling applies only in exceptional cases (e.g. dinners at residential meetings for senior consultants, learned-society conferences with substantial educational content); costs "should normally be well below this figure." The £75 cap does not apply to events outside the UK in other EFPIA member countries, where host-country limits apply instead. | Per-person subsistence cost records against the £75 ceiling, with justification on file for any spend approaching that ceiling (given it's meant to be exceptional, not routine); for non-UK EFPIA-country events, confirmation the applicable host-country limit (not the UK £75 figure) was used. |
| 10.9 | Payments to doctors/prescribers (individually or as groups), directly or indirectly, for room rental for events/meetings are prohibited — including via equipment funds, patients' comfort funds, or charities. Payment to postgraduate medical centres is not precluded. | Room-hire payment records checked for the actual payee entity — a payment routed through an intermediary fund/charity to a prescriber group is still non-compliant. |
| 10.10 | Sponsorship of an event/meeting "must be disclosed in all related material and published proceedings," with the sponsorship declaration "sufficiently prominent to ensure that readers are aware of it at the outset." | A visible sponsorship declaration on all event material and any published proceedings, positioned/sized so it isn't missed. |
| 10.11 / 10.12 | Companies must publicly disclose annually the financial details of (10.11) support to individual UK health professionals/decision-makers for event attendance, and (10.12) sponsorship contributions paid to healthcare/patient organisations or event-managing organisations — both under Clause 28's disclosure mechanism (see below), covering direct and indirect payment, inside and outside the UK. | Disclosure records for both categories, cross-referenced against the Clause 28 disclosure filing to confirm nothing supported under Clause 10 was omitted from the annual disclosure. |
| Common failure pattern (whole section) | The most granular, quantifiable sub-clauses (10.5/10.6's £6 item cap, 10.8's £75 subsistence ceiling) are also the easiest for a document/expense-record review to catch objectively — a hospitality record with a subsistence line item exceeding £75/person without an "exceptional circumstance" justification on file is a directly citable gap. The 10.4 "written agreement + pre-documented rationale" requirement is a common two-part gap: an agreement often exists, but the rationale is written up after the fact rather than genuinely pre-documented. | |
Clause 18 — Information, Claims and Comparisons
| Clause | Requirement (near-verbatim) | Evidence |
|---|
| 18.1 | "Upon reasonable request, a company must promptly provide health professionals and other relevant decision makers with accurate and relevant information about the medicines which the company markets." | A documented, responsive medical-information process for HP/ORDM enquiries — the general obligation underlying the specific 10-working-day SLA in 18.2/14.3. |
| 18.2 | Substantiation for any claim/comparison must be provided "as soon as possible, and certainly within ten working days" of an HP/ORDM request; SPC provision can substantiate marketing-authorisation-approved indications. | Same 10-working-day substantiation-turnaround evidence already flagged under Clause 14.3 — 18.2 is the mirror obligation. |
| Common failure pattern | Identical structural risk to Clause 14.3 — a documented process without turnaround-time evidence is a partial gap; the clause explicitly permits the SPC itself to satisfy substantiation for authorised-indication claims, a lower bar than companies sometimes assume is required. | |
Clause 19 — Prohibition on Inducements and Inappropriate Payments and the Provision of Items to Health Professionals and Other Relevant Decision Makers
| Clause | Requirement (near-verbatim) | Evidence |
|---|
| 19.1 | "No gift, pecuniary advantage or benefit may be supplied, offered or promised to health professionals or to other relevant decision makers in connection with the promotion of medicines or as an inducement to prescribe, supply, administer, recommend, buy or sell any medicine," subject to specific named exceptions (Clause 10.5 low-value items; Clause 19.2 patient-support material). Gift voucher schemes are specifically prohibited. Package deals (administration apparatus, training, professional services bundled with a medicine purchase) are permitted only where "fair and reasonable" and relevant to the medicine. Outcome/risk-sharing refund arrangements are acceptable only where criteria are settled in advance and any refund goes to the NHS/relevant organisation, never to an individual practitioner. | A gift/benefit register (or the absence of any such items) checked against the named exception list — any item not falling within Clause 10.5 or 19.2 is presumptively prohibited; package-deal documentation showing the "fair and reasonable, relevant to the medicine" test was applied and recorded; outcome/risk-sharing agreements confirming the refund recipient is an institution, not an individual. |
| 19.2 | Patient-support materials distributed via health professionals are permitted only if inexpensive, genuinely of benefit to patient care, and certified in advance under Clause 8.3. | The Clause 8.3 certification record for the specific patient-support item, plus a cost/benefit rationale confirming it is genuinely patient-care-related rather than a disguised inducement. |
| Common failure pattern (whole section) | Promotional items intended for personal use (mugs, stationery, general household goods) are explicitly named as unacceptable in PMCPA's own guidance — the recurring failure pattern is an item that is nominally low-cost but fails the "genuine patient/professional benefit, not personal benefit" test rather than failing on cost alone. | |
Clause 20 — Collaborative Working with Organisations
| Clause | Requirement (near-verbatim) | Evidence |
|---|
| 20.1 | Collaborative working is acceptable where it "either enhances patient care or is for the benefit of patients or alternatively benefits the NHS and, as a minimum, maintains patient care," carried out compatibly with the Code. Joint working is a limited form of collaborative working (see 20.4). | Classification of the arrangement as collaborative working (vs. a straightforward grant/sponsorship) against this benefit test. |
| 20.2 | Must have and be able to demonstrate "the pooling of skills, experience and/or resources from all of the parties involved," shared commitment to delivery, and significant contribution from each party. | Evidence of genuine multi-party resource/skill pooling — not a company-funded project with a passive healthcare-organisation counterparty. |
| 20.3 | Must additionally: not constitute an inducement to prescribe/supply/etc.; be open and transparent; be prospective; be documented in a formal written agreement kept on record; and have a summary of the agreement publicly available before arrangements are implemented. | A written agreement plus a pre-implementation public summary — two distinct, sequenced documentary requirements. |
| 20.4 | Joint working (NHS + one or more pharma companies, patient-centred, benefiting patients) is an acceptable form of collaborative working under Clause 20, but "collaborative working which relies on benefiting the NHS and maintaining patient care will not meet the requirements for a joint working project" — a stricter subset test. | Confirmation the specific "joint working" label (if used) meets the stricter patient-benefit-not-just-NHS-benefit test, not just the general Clause 20.1 minimum. |
| 20.5 | "Transfers of value made by companies in connection with collaborative working must be publicly disclosed annually," giving the amount/value and recipient name — disclosed per Clause 28, regardless of whether value is transferred to a healthcare organisation or via another funding model. | Cross-reference to Clause 28 disclosure filing for the specific collaborative-working line item. |
| Certification | Material relating to collaborative working must be certified, including the project initiation document and the summary of the collaborative working agreement — the collaborative working agreement itself does not need to be certified, only the final documents. | Certification records for the project initiation document and agreement summary specifically — noting the agreement itself is explicitly exempt, a nuance easy to get backwards. |
| Common failure pattern (whole section) | The written agreement's required content list is extensive — project name/parties/dates, benefits stated first before outcomes, financial arrangements, roles, publication plans, contingency/dispute-resolution/exit clauses — making partial agreements (missing the exit-criteria or publication-plan elements specifically) a plausible gap pattern, structurally similar to Clause 10.4's two-part agreement-plus-rationale trap. | |
Clause 21 — Provision of Medicines and Samples
| Clause | Requirement (near-verbatim) | Evidence |
|---|
| 21.1 | Samples only to HPs qualified to prescribe the product — never to ORDMs. | Recipient-eligibility check against the HP-only rule. |
| 21.2 | Max four samples of a particular medicine per HP per year; samples of a given medicine may be provided for no more than two years after that HP's first sample request (with a defined "new medicine" exception for genuine new marketing authorisations, not mere pack/strength extensions). | Per-HP sample count and duration tracking against the 4/year and 2-year caps. |
| 21.3 | Samples only against signed, dated written requests (electronic signature acceptable); requests retained ≥1 year. | Signed/dated request records, retained for the minimum period. |
| 21.4 | Sample must be no larger than the smallest marketed presentation. | Pack-size comparison check. |
| 21.5 | Each sample marked "free medical sample – not for resale" (or equivalent) and accompanied by an SPC copy. | Labelling and SPC-inclusion check. |
| 21.6 | Prohibited for medicines containing certain Narcotic Drugs Convention / Psychotropic Substances Convention scheduled substances (with narrow exemptions). | Controlled-substance schedule check before any sample provision. |
| 21.7 | "Adequate systems of control and accountability for samples... and for all medicines handled by representatives," tracking per-HP quantities against the 21.2 cap. | An auditable sample-control system — stock security, expiry-date audits, return tracking. |
| 21.8 | Posted medicines must be packed child-resistant-secure; no unsolicited medicine may be posted. | Packaging-standard and solicitation-record check for any postal distribution. |
| 21.9 | Medicines may not be sold/supplied to the public for promotional purposes. | Confirms this is an HP/ORDM-only mechanism entirely. |
| 21.10 | Samples must not be provided "simply as an inducement to prescribe... or for the sole purpose of treating patients." | Purpose-of-provision check distinguishing legitimate familiarisation samples from disguised inducement or treatment supply. |
| Common failure pattern (whole section) | Starter packs are explicitly named as not permitted at all — a specific, easily-missed prohibition distinct from the general sample rules, since starter packs superficially resemble legitimate samples but fail the clause's underlying purpose test. | |
Clause 22 — Non-Interventional Studies of Marketed Medicines
| Clause | Requirement (near-verbatim) | Evidence |
|---|
| 22.1 | Prospective non-interventional studies must be conducted for a scientific purpose and meet a multi-part checklist: written study plan/protocol and written contracts specifying services/payment; ethics-committee submission where applicable; reasonable/fair-market remuneration; must not be an inducement to prescribe; scientific-service certification of the protocol and supervision of conduct; timely results analysis/summary distribution to participating HPs (and to the competent authority if benefit/risk-relevant); representatives limited to a supervised administrative role only, not linked to promotion. | A study file addressing each named element — protocol, contracts, ethics submission (where relevant), remuneration basis, scientific-service certification, results-summary distribution record, and a representative-role definition confirming administrative-only involvement. |
| 22.2 | Companies are "encouraged" (not mandated) to extend 22.1's criteria to other non-interventional study types (epidemiological, registries, retrospective). | A judgment call — retrospective/registry studies are lower-priority for hard 22.1-checklist enforcement but should still be reviewed against it as best practice. |
| 22.3 | Summary details/results must be published consistent with Clause 4.6 clinical-trial obligations. | Cross-reference to Clause 4.6 publication discipline. |
| Common failure pattern | The representative-involvement restriction (administrative only, scientific-service-supervised, "not linked to the promotion of any medicine") mirrors the same representative/service-provider boundary problem flagged under Clause 23's donations-in-service-form provisions — a recurring structural risk wherever representatives touch a non-promotional activity. | |
Section 4 — Broad Stakeholder Interactions
Clause 23 — Donations and Grants
| Clause | Requirement (near-verbatim) | Evidence |
|---|
| 23.1 | Donations/grants are funds, benefits-in-kind, or services "freely given for the purpose of supporting healthcare, scientific research or education, with no consequent obligation on the recipient... to provide goods or services to the benefit of the pharmaceutical company in return." Donations and grants to individuals are prohibited — only organisations qualify. | Confirmation the recipient is an organisation, not an individual, and that no reciprocal-benefit obligation exists in the arrangement. |
| 23.2 | To healthcare/patient/other organisations, only if: for supporting healthcare/research/education; not an inducement to recommend/prescribe/purchase/supply/sell/administer specific medicines; prospective; not medicine-branded (company name permitted). Plus: written agreement required (per-organisation content spec below); agreement (and service-provider instructions where relevant) certified in advance per Clause 8.3; records kept; disclosed annually per Clauses 28 and 29. | A written, Clause 8.3-certified agreement matching the specified content list (description, objective, parties/roles, activity type, timeframe, funding amount/breakdown, acknowledgement statement, signatories, date) plus a disclosure cross-reference to Clause 28/29. |
| Representative-role rules | Representatives may introduce a donation/grant-call announcement only briefly, may not instigate detailed discussion at the same call as product promotion, and — critically — may not offer a donation/grant to facilitate a medication switch just agreed during a promotional call (this would constitute inducement). For donations in service form: only suitably qualified non-representative staff may have patient contact/records access; service-provider remuneration must not be sales-linked; providers need detailed written instructions (comparable to Clause 17.8 briefing material); recipients need sufficient written information to avoid misunderstanding; materials must be non-promotional; service materials require Clause 8.3 certification; copies available to PMCPA on request. | A representative-conduct policy explicitly addressing the switch-facilitation trap; for service-form donations, a service-provider instruction pack meeting all listed criteria, with sales-delinked remuneration confirmed and Clause 8.3 certification on file for the materials. |
| Switch/therapy-review distinction | Company-paid/facilitated switch services (changing a patient's medicine without clinical assessment, at the sponsoring company's expense) are prohibited outright under 19.1/23.1. A genuine therapeutic review (clinical-assessment-driven, covering a comprehensive range of options including non-medicinal ones, not limited to the sponsor's own products) is acceptable, provided each individual change decision is documented with rational-grounds evidence. | For any company-supported medication-review programme, evidence it is a genuine multi-option clinical review (not a disguised switch service) — per-patient documented rationale for any treatment change. |
| Common failure pattern | The representative-role list is the clause's most granular and most likely partial-compliance zone — specifically, the "cannot offer a donation to facilitate a switch agreed in the same call" rule is a subtle timing/sequencing trap distinct from a donation being improper in isolation. | |
Clause 24 — Contracted Services
| Clause | Requirement (near-verbatim) | Evidence |
|---|
| 24.1 | HPs, ORDMs (or employers on their behalf), healthcare/patient organisations, individuals representing patient organisations, and members of the public (including patients/journalists) may be engaged as consultants/advisors — speaking/chairing, medical/scientific study or clinical-trial involvement, training, writing, advisory boards, market research — "where such participation may involve remuneration and/or hospitality." | A contracted-services register naming each contracted party, role type, and remuneration/hospitality basis. |
| 24.2 | A nine-point compliance checklist for genuine consultancy: advance written contract specifying services/payment basis; documented legitimate need identified before contracting; selection criteria tied to that need, chosen by qualified selectors; number of contractors/extent of service not exceeding genuine need; records of services actually provided/used maintained; hiring must not be an inducement to prescribe etc.; remuneration must reflect fair market value — "token consultancy arrangements must not be used to justify compensating the contracted party"; contracts must require the individual to declare the contracted relationship whenever speaking/writing publicly on a related matter. | For each contract: pre-need documentation dated before contracting; selection-criteria record; fair-market-value remuneration benchmarking (not just a fixed fee assumption); actual-services-rendered record; and the public-disclosure-obligation clause present in the contract text itself. |
| 24.3 | Contracts for any non-Code-covered service type with HPs/ORDMs/employers/healthcare organisations/patient organisations/individuals/public are allowed if provided to support "healthcare, research or education" and not an inducement to recommend/prescribe/purchase/supply/sell/administer a specific medicine. | Purpose-and-non-inducement test applied to services outside the named 24.1 categories. |
| 24.4 | Annual public disclosure of UK fees/expenses for contracted services (chairing/speaking, training assistance, advisory boards, etc.), including R&D-related payments (clinical trials). | Cross-reference to the Clause 28 disclosure filing for contracted-service line items. |
| 24.5 | Market-research payments to contracted individuals must additionally be disclosed unless the company genuinely does not know participant identities (identity-unknown research is exempt from this specific disclosure). | Confirmation of whether participant identity was known to the company — this determines whether 24.5 disclosure applies at all. |
| 24.6 | Detailed disclosure specs differing by recipient type: institution/organisation vs. individual HP/ORDM (total amount per contracted individual, names disclosed except for R&D/clinical-trial payments, which are aggregate-only) vs. patient organisations (per Clause 29 — payment to an individual representing a patient organisation is disclosed as a payment to that organisation, and the contract itself should be made with the organisation, not the individual) vs. members of the public (per Clauses 30/31 — aggregate count/total, names not required). Fees and expenses disclosed separately throughout. | A disclosure reconciliation confirming the correct disclosure tier (named-individual vs. aggregate vs. organisation-attributed) was applied per recipient category — R&D/clinical-trial payments specifically checked for aggregate (not named) treatment. |
| Common failure pattern (whole section) | 24.2's "token consultancy" prohibition and the mandatory public-declaration-of-relationship contract clause are the two most substantively-checkable sub-requirements in an uploaded contract document — a consultancy fee with no fair-market-value benchmarking on file, or a contract silent on the individual's public-declaration obligation, are both direct textual gaps. The patient-organisation contracting rule (contract must be with the organisation, not the individual representative) is a structural trap similar to Clause 27.5's mirror requirement. | |
Clause 25 — Relationships with Health Professionals, Other Relevant Decision Makers, Healthcare Organisations and Patient Organisations
| Clause | Requirement (near-verbatim) | Evidence |
|---|
| 25.1 | "No company may require that it be the sole funder or sponsor of a healthcare organisation or patient organisation or any of its programmes." | Sponsorship agreement checked for any exclusivity clause — a sole-funder requirement is itself a breach regardless of amount. |
| 25.2 | A company "must not make public use of a healthcare organisation or patient organisation's logo and/or proprietary material without the organisation's written agreement," with the specific purpose/use clearly stated when seeking permission; even with permission, use "must not be such as to otherwise breach the Code." | Written permission record naming the specific stated purpose/use of the logo/material — permission alone doesn't clear other Code requirements (e.g., disguised promotion). |
| 25.3 | "Companies must ensure that all sponsorship is clearly acknowledged from the outset. The wording of the declaration of sponsorship must be unambiguous and accurately reflect the extent of the company's involvement and influence over the material." | Same sponsorship-declaration standard as Clause 5.6/10.10 — checked specifically for accuracy about the extent of influence, not just the fact of involvement. |
| 25.4 | Market research, clinical assessments, post-marketing surveillance/experience programmes, and post-authorisation studies (including retrospective) "must not be disguised promotion" and "must be conducted with a primarily scientific or educational purpose." Market research's data-collection phase and any subsequent promotional use of the resulting statistics "must be kept distinct," and the commissioning company's identity must be revealed to PMCPA on request (including via an agency conducting research on the company's behalf). | Confirmation the research/surveillance activity is genuinely scientific in design and separated in time/process from any promotional use of its outputs; agency-commissioned research checked for a client-identity-disclosure mechanism to PMCPA. |
| Common failure pattern | 25.4's phase-separation requirement (research collection vs. promotional use of results) is the clause's most fact-sensitive test, structurally similar to Clause 26.1's advertising/information boundary — the same underlying activity can be legitimate research or disguised promotion depending on sequencing and stated purpose, not content alone. | |
Section 5 — Public and Patient Organisation Interactions
Clause 26 — Relations with the Public, Including Patients and Journalists
| Clause | Requirement (near-verbatim) | Evidence |
|---|
| 26 (chapeau) | Draws attention to the quality-standard clauses (5–10) applying equally to public-facing material, not just HP-facing promotion. | Any public/patient-facing document checked against Clauses 5, 6, 8, etc. as well as Clause 26 specifically — not treated as a lower-bar category. |
| 26.1 | "Prescription only medicines must not be advertised to the public." A specific, narrow exception exists for vaccination campaigns approved by health ministers, which must still reference adverse-event reporting and comply with the rest of the Code. | Confirmation the document does not constitute public advertising of a POM — a boundary check between permitted "information provision" and prohibited "advertising," which the Code itself treats as a substantive, fact-specific distinction. |
| 26.2 | Information about POMs provided to the public "must be factual and presented in a balanced way," must not encourage the public to ask a health professional to prescribe a specific named medicine, and must not raise unfounded hopes of treatment success. PMCPA's guidance distinguishes three categories: proactive information (unsolicited — booklets, press releases), reference information (comprehensive website resources — SPCs, patient leaflets, appraisals), and reactive information (direct-inquiry responses) — each with different applicable handling expectations. | Content classified into one of the three named categories, with the corresponding handling standard applied; specific check that no line in the material functions as a request-prompt for a named medicine. |
| 26.3 | Patient-support items must be "inexpensive" (maximum £15 excluding VAT) and related to the patient's condition or general health; companies must not sponsor competitions offering prizes to patients. | Cost records for patient-support items against the £15 cap; confirmation no prize-based competition is sponsored. |
| 26.4 | Patient-facing material for a specific medicine must include the obligatory Yellow Card adverse-event reporting statement (the patient-facing analogue of Clause 12.6); medicines under additional monitoring require the black-triangle symbol (the patient-facing analogue of Clause 12.7). | Yellow Card statement and (where applicable) black triangle present on patient-facing material — checked as a distinct requirement from the HP-facing Clause 12 version, not assumed to be automatically satisfied by it. |
| 26.5 | "Requests from individual members of the public for advice on personal medical matters must be refused" — companies should redirect to healthcare professionals, NHS resources, or patient organisations. | For any company-public interaction channel (e.g. a patient-facing web form or helpline script reviewed as a document), confirmation the response protocol redirects rather than offers personal medical advice. |
| Common failure pattern | The 26.1 boundary between permitted disease/medicine information and prohibited POM advertising to the public is a genuinely fact-sensitive line (tone, framing, and whether the material prompts a specific request) rather than a simple keyword check — flagged here as a clause where Regscribe's citation-grounded reasoning is especially valuable versus a naive banned-word scan, but also one where false positives/negatives are more likely without careful prompt design. | |
Clause 27 — Relationships with Patient Organisations
| Clause | Requirement (near-verbatim) | Evidence |
|---|
| 27.1 | Companies must: respect and assure patient/user-organisation independence (political judgement, policies, activities); base relationships on mutual respect with equal-value input; not promote or request promotion of a specific POM; ensure objectives/scope are transparent and support is "always clearly acknowledged." | An independence-and-transparency check on any patient-organisation relationship — specifically confirming no POM-promotion request is embedded in the arrangement. |
| 27.2 | Donations/grants/sponsorship to patient organisations require a written agreement per donation/grant/sponsorship, with a specific content list (description, objective/how it supports healthcare-research-education, named parties/roles, activity type/contribution nature, timeframe, funding amount or in-kind description with cost breakdown where possible, acknowledgement statement, signatories, date). Agreement must be certified per Clause 8.3; resulting materials/activities also certified where covered by 8.3; disclosed annually per Clause 29. | The written agreement itself checked against the full content-list, plus its Clause 8.3 certification record and Clause 29 disclosure cross-reference. |
| 27.3 | Must comply with the POM-to-public advertising prohibition; company involvement "made clear," with declaration wording "accurately reflect[ing] the nature of the company's involvement." | Same accuracy-of-declaration test as Clause 25.3, applied to patient-organisation-facing material specifically. |
| 27.4 | A company "must not seek to influence the text of patient organisation material in a manner favourable to its own commercial interests" — correcting factual inaccuracies is explicitly permitted; at the patient organisation's request, companies "may contribute to the drafting of patient organisation materials from a fair and balanced and scientific perspective." | Editorial-influence check — company input on patient-organisation material limited to factual correction or explicitly-requested, balanced drafting contribution, not commercially-favourable framing. |
| 27.5 | Contracted services with patient organisations/individuals representing them must comply with Clause 24, be disclosed annually per Clause 29, and contracts should include a public-declaration-of-relationship obligation (comparable to Clause 24.2's). Contracts with individuals representing patient organisations should be made with the patient organisation itself, and payment disclosed as a payment to that organisation, not the individual. | Contract-counterparty check — confirming the patient organisation, not the representing individual, is the actual contracting party; disclosure attributed accordingly. |
| Common failure pattern | 27.5's "contract with the organisation, not the individual representative" rule is the clause's most structurally distinctive trap — a company contracting directly with a named patient-organisation representative (rather than the organisation) creates both a Clause 27.5 documentation defect and a Clause 24.6/29 disclosure-attribution error simultaneously. | |
Section 6 — Annual Disclosure Requirements
Clause 28 — Annual Disclosure of Transfers of Value to Health Professionals, Other Relevant Decision Makers and Healthcare Organisations
| Clause | Requirement (near-verbatim) | Evidence |
|---|
| 28.1 | Companies must document and publicly disclose annually certain transfers of value made directly or indirectly to health professionals, other relevant decision makers, and healthcare organisations in Europe (including company employees who are practising health professionals), via the Disclosure UK platform, using PMCPA's mandatory templates. | A completed Disclosure UK submission for the relevant year, using the current mandatory template — a submission on an outdated template format is a documentary defect independent of the underlying figures' accuracy. |
| 28.2 | Covered transfer categories: collaborative working (Clause 20, not independently verified); donations/grants (Clause 23, not independently verified); contracted-service fees (Clause 24.6, not independently verified); event-attendance support (Clause 10.11); professional service fees; event-sponsorship contributions (Clause 10.12). Where a company contributes to subsistence costs for a healthcare-organisation-sponsored event, that cost must be included in the sponsorship disclosure; individual health-professional attendance support does not require subsistence to be separately disclosed. | A disclosure line-item reconciliation confirming every payment category named in 28.2 that actually occurred during the year is represented in the Disclosure UK submission — cross-referenced against Clause 10.11/10.12 event records specifically. |
| 28.3 | Transfer-of-value categories to individual professionals may be aggregated category-by-category, provided itemised detail is available on request to the recipient or relevant authorities; payments to healthcare organisations must be disclosed per-activity, not aggregated. | Confirmation the organisation-level disclosures are itemised per activity (not rolled up), while individual-level aggregation (where used) is backed by a retrievable itemised breakdown. |
| 28.4 | Where a transfer reaches an individual indirectly (e.g. routed through an organisation), disclosure happens once, preferably attributed to the individual recipient — not double-counted at both the organisation and individual level, and not omitted entirely on the assumption "the organisation already reported it." | A traceability record showing indirect transfers were attributed to a single disclosure point, with the routing organisation identified. |
| 28.5 | Recipients who cannot be individually identified (e.g. consent withheld) must still be disclosed in aggregate — showing recipient count, percentage of total transfers this represents, and total amount. Companies should first pursue a lawful basis for individual disclosure before falling back to aggregation. | An aggregate-disclosure line item (count/percentage/total) for any consent-withheld or otherwise non-attributable transfers, plus documented evidence an individual-disclosure lawful basis was genuinely pursued first rather than aggregation being used as a default. |
| 28.6 | Companies must publish a methodology note describing their recognition approach, treatment of multi-year contracts, VAT/tax treatment, currency conversion, and timing conventions used in the disclosure. | A published methodology note accompanying the disclosure, addressing each of the five named elements — a disclosure filing without an accompanying methodology note is itself an incomplete submission under 28.6. |
| Common failure pattern | The 28.4 indirect-transfer attribution rule (single-point disclosure, preferably to the individual) is a common source of both double-counting and under-disclosure in practice, per the structure of the clause itself — a company disclosing at the organisation level and separately at the individual level for the same underlying payment, or disclosing at neither level on the mistaken assumption the other party covers it, are the two failure modes the clause's "disclosure happens once" language is specifically designed to prevent. | |
Clause 29 — Annual Disclosure of Contracted Services, Donations, Grants and Sponsorship Provided to Patient Organisations
| Clause | Requirement (near-verbatim) | Evidence |
|---|
| 29.1 | Companies must publish annually, on the company website (national or European level), a list of patient organisations receiving donations/grants/sponsorship (including event/meeting-related) or engaged for contracted services, covering a full calendar year, plus a methodology note. For 2024-onward transfers, disclosure is via a link from the Disclosure UK gateway to the company's own website publication. | The published list plus accompanying methodology note; the Disclosure UK gateway link resolving correctly to the company's own hosted disclosure page. |
| 29.2 | Disclosure must include, per Clause 23/10: monetary value of each financial contribution with a sufficiently complete description; monetary value (or, where not meaningfully monetisable, a clear qualitative description) of each non-financial/indirect support item; per Clause 24: total amount paid per patient organisation per calendar year with a sufficiently complete service description, fees/expenses disclosed separately. | Line-item disclosure reconciliation confirming both financial and non-financial/in-kind support are represented, with fees/expenses split out. |
| Common failure pattern | The optional-but-recommended PMCPA disclosure template and the gateway-link mechanism (new from 2024 onward) are both process/format elements distinct from the underlying figures' accuracy — a functioning Disclosure UK link that fails to actually land on a complete, correctly-formatted company disclosure page is a documentary defect independent of whether the underlying payments were properly made. | |
Clause 30 — Annual Public Disclosure of Contracted Services Provided by the Public, Including Patients and Journalists
| Clause | Requirement (near-verbatim) | Evidence |
|---|
| 30.1 | Annual public disclosure (on the company website) of fees for contracted services (speaking, training assistance, writing, advisory boards, clinical-trial design advice, market research) paid to UK public members including patients/journalists, where remuneration/travel was involved. Must include: total number of contracted members of the public and total amount paid per calendar year, with a sufficiently complete service description; a breakdown by group (public/patients/journalists); fees/expenses disclosed separately; plus a methodology note. Disclosure via the Disclosure UK gateway link mechanism (as with Clause 29). | The published aggregate figures (count, total amount, per-group breakdown), methodology note, and working gateway link — names are explicitly not required to be disclosed here (unlike named-HP disclosure under Clause 28). |
| Common failure pattern | The aggregate-only, no-names requirement here is the inverse of Clause 28's named-individual-preferred approach for HPs — a company defaulting to its Clause 28 disclosure habits (attempting individual attribution) for public/patient/journalist contracted services would be over-disclosing relative to what 30.1 actually requires, worth flagging as a distinct (over-disclosure) risk pattern rather than only under-disclosure. | |
Clause 31 — Timings, Duration and Retention of Disclosure Information
| Clause | Requirement (near-verbatim) | Evidence |
|---|
| 31.1 | Disclosures made annually per calendar year, "in the first six months after the end of the calendar year in which the transfers of value/payments were made." | Disclosure-publication date checked against the six-month post-year-end deadline. |
| 31.2 | Disclosed information "must remain in the public domain for at least three years from the time of first disclosure." | Retrievability check confirming a disclosure from up to three years prior is still live/published, not taken down early. |
| 31.3 | Companies "must document all disclosures and retain the records for at least five years after the end of the calendar year to which they relate." | Internal retention record distinct from the public-facing three-year window — five years from year-end, and this is an internal-documentation obligation, not just the public page's uptime. |
| Common failure pattern | The three distinct clocks in this clause (6-month publication deadline, 3-year public-domain minimum, 5-year internal-retention minimum) are easy to conflate into a single "keep for a few years" practice — the internal 5-year retention specifically outlives the public 3-year window, meaning a company that takes down public disclosure pages at the 3-year mark while treating that as also satisfying 31.3's internal-record retention would be non-compliant on the internal-documentation leg even though the public-facing leg was met. | |
Glossary (Clause 1's own definitions — reference, not scored directly)
- Health professional: "Any member of the medical, dental, pharmacy or nursing profession and any other person who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine."
- Other relevant decision maker (ORDM): particularly someone with an NHS role who could influence administration, consumption, prescription, purchase, recommendation, sale, supply, or use of a medicine, but who is not themselves a health professional (e.g. an NHS procurement/formulary decision-maker).
- Promotion: any activity undertaken by (or with the authority of) a pharmaceutical company that promotes administration, consumption, prescription, purchase, recommendation, sale, supply, or use of its medicines — a broad definition explicitly including advertising, representative activity, samples, inducements, hospitality, and event sponsorship, while excluding certain narrow categories (e.g. unsolicited factual replies, factual announcements).
- Transfer of value: any direct or indirect transfer of value, in cash, in-kind, or otherwise, made in connection with the development or sale of medicines, whether or not for promotional purposes — with specific named exclusions (e.g. OTC-only transfers, routine medicine purchases, samples covered under Clause 21).
- Healthcare organisation: a healthcare/medical/scientific association or organisation (hospital, clinic, foundation, university/teaching institution, learned society) based/incorporated/primarily operating in Europe, or an organisation through which health professionals/ORDMs provide services.
- Patient organisation: an organisation mainly comprised of patients and/or caregivers, or a user organisation (disability, carer/relative, consumer organisation) representing/supporting patients' or caregivers' needs.
Use these definitions to correctly classify a document's audience and recipients before scoring — several clauses above (10.4/10.11 vs. 10.12, 26 vs. 12, 28.3's individual-vs-organisation split) apply differently depending on whether the recipient is a health professional, an ORDM, a healthcare organisation, or a member of the public/patient.
Common failure patterns (cross-cutting summary — sourced from PMCPA's own 2024 Annual Report)
Sourcing caveat: every figure below is taken directly from PMCPA's Annual Report 2024 PDF (pmcpa-annual-report-2024-final.pdf), fetched and extracted via pdftotext -layout — not from a secondary/trade-press summary. Note the report's own framing: 2024 figures largely describe complaints received in 2024 (264 total) while outcome/ruling statistics for a given year lag by roughly a year, since cases take time to resolve — the report explicitly presents most breach-rate figures against the 2023 complaint cohort, with 2024's own cohort still largely "not yet complete" (57 of 121 cases) as of the report's 1 July 2025 data cut.
- Overall volume: PMCPA received 264 complaints in 2024; of these, 69 did not relate to a pharmaceutical company at all (outside PMCPA's jurisdiction — typically promotion of a POM to the public by a pharmacy, clinic, or online influencer, redirected to the ASA or MHRA) and 47 were not proceeded past initial review (most commonly for lack of evidence of a possible breach, data-privacy concerns, or being outside Code scope). 121 cases were proceedable in 2024 (down from 130 in 2023).
- Breach rate: for the 2023 complaint cohort (the most complete year reported), 85 of 130 cases (65%) resulted in at least one breach finding; at the level of individual "matters" (each separate allegation within a case) ruled upon, 252 of 598 matters (42%) were found in breach. The report's own narrative states this "remained broadly consistent with those received in previous years — approximately two-thirds of complaints ruled upon result in at least one breach ruling."
- Clause 2 (industry-discredit) breaches — the most reputationally severe finding — occurred in 11 cases (11 rulings) for the 2023 cohort (versus 14 cases/16 rulings in 2022, 16 cases/17 rulings in 2021); companies found in breach of Clause 2 for the 2023 cohort are individually named in the report and marked with an asterisk in its "Companies ruled in breach" list — the named list includes major UK-market pharmaceutical companies across multiple therapeutic areas, confirming Clause 2 breaches are not rare/isolated events.
- Appeals are relatively rare and mostly unsuccessful for complainants: of 2023-cohort cases, only 13 (10%) were appealed, with 8 (6%) resulting in a successful or partly-successful appeal; of complainant-initiated appeals specifically, the report shows a materially lower success rate than respondent(company)-initiated appeals. 90% of cases are resolved at Panel level without reaching the Appeal Board.
- Sanctions beyond a breach ruling itself are uncommon: for the 2023 cohort, the report shows 0 required suspensions of materials, 0 required corrective statements, 1 public reprimand, and 1 audit — reinforcing that the primary real-world consequence of most breach rulings is the public ruling and associated reputational cost (per Clause 2's own "particular censure" framing) rather than an additional formal sanction layer.
What this means for Regscribe's scoring: the two-thirds-of-cases/roughly-40%-of-matters breach rate, and the recurring co-occurrence of Clause 5.1/6.1/2 findings alongside a specific factual clause (6.2, 8.1, 12.x), together suggest promotional-material review failures in practice are rarely single-clause, isolated defects — a document with one substantive gap (e.g. a missing Clause 12.6 adverse-event statement) often also attracts a general Clause 5.1/2 finding for falling short of the Code's overall standard. Regscribe's citation-grounded, multi-clause simultaneous review approach is well matched to this real-world pattern, versus a single-clause pass/fail check.
Gaps / follow-ups before this goes into production scoring
- All 31 clauses are now fetched and scored (12 in the original pass — 2, 5, 6, 8, 10, 12, 14, 19, 26, 28, plus definitions — and the remaining 19 — 3, 4, 7, 9, 11, 13, 15–18, 20–25, 27, 29–31 — in a follow-up pass, extracted directly from the consolidated Code PDF via
pdftotext -layout). Caveat carried forward: the failure-pattern rows for the 19 clauses added in the follow-up pass are inferred from each clause's own structure (multi-part requirements, common two-step documentation traps), not cross-checked against PMCPA's 2024 Annual Report's named-breach data the way the original 12 clauses' failure-pattern rows were — a lighter-weight signal than the original entries until a dedicated pass re-examines the Annual Report's named-breach list for citations against these specific clause numbers.
- PMCPA's individual case reports/rulings database (
pmcpa.org.uk/cases/completed-cases/) was identified via search but not systematically fetched or analysed — the Annual Report's aggregate statistics (above) are real and directly sourced, but a richer set of clause-specific "common failure pattern" examples (comparable to the named FDA Warning Letter / MHRA deficiency excerpts used in other Regscribe rubrics) could be built from a follow-up pass pulling several completed case rulings directly — particularly valuable for the financially/contractually complex clauses (20 Collaborative Working, 23 Donations and Grants, 24 Contracted Services) where real ruling examples would meaningfully sharpen the failure-pattern rows.
- No breach-rate breakdown by individual clause number was found in the Annual Report — the report reports Clause 2 breaches by name (a PMCPA convention, since Clause 2 breaches are separately tracked as the most severe finding) but does not publish a table of "breaches by clause number" the way MHRA's GMP inspection deficiency data does for Annex 11. This is a genuine data gap in the source itself, not an extraction failure.
- Scope/jurisdiction verification is company-specific and out of scope for this rubric to resolve generically — per the "READ THIS FIRST" section above, the Code binds ABPI members and jurisdiction-accepting non-members; whether a specific company using Regscribe is actually bound should be confirmed per-engagement rather than assumed, and is flagged as a product/onboarding consideration rather than a rubric-content gap.